Literature DB >> 26586766

Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development.

Nadya Dimitrova1, Vasilena Gocheva2, Arjun Bhutkar2, Rebecca Resnick2, Robyn M Jong2, Kathryn M Miller2, Jordan Bendor2, Tyler Jacks3.   

Abstract

UNLABELLED: The two unrelated miRNAs miR-143 and miR-145, coexpressed from the miR-143/145 cluster, have been proposed to act as tumor suppressors in human cancer, and therapeutic benefits of delivering miR-143 and miR-145 to tumors have been reported. In contrast, we found that tumor-specific deletion of miR-143/145 in an autochthonous mouse model of lung adenocarcinoma did not affect tumor development. This was consistent with the lack of endogenous miR-143/145 expression in normal and transformed lung epithelium. Surprisingly, miR-143/145 in the tumor microenvironment dramatically promoted tumor growth by stimulating the proliferation of endothelial cells. Loss of miR-143/145 in vivo led to derepression of the miR-145 target CAMK1D, an inhibitory kinase, which when overexpressed prevents mitotic entry of endothelial cells. As a consequence, tumors in miR-143/145-deficient animals exhibited diminished neoangiogenesis, increased apoptosis, and their expansion was limited by the tumor's ability to co-opt the alveolar vasculature. These findings demonstrate that stromal miR-143/145 promotes tumorigenesis and caution against the use of these miRNAs as agents in cancer therapeutics. SIGNIFICANCE: This study shows that miR-143/145 expressed from the tumor microenvironment stimulates neoangiogenesis and supports tumor expansion in the lung, demonstrating a surprising role for the putative tumor suppressor miRNA cluster in promoting tumorigenesis. We propose inhibition of miR-143/145 as a therapeutic avenue to modulate tumor neoangiogenesis. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26586766      PMCID: PMC4744583          DOI: 10.1158/2159-8290.CD-15-0854

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  45 in total

1.  miR-145 Contributes to Hypertrophic Scarring of the Skin by Inducing Myofibroblast Activity.

Authors:  Christiane Gras; Dominica Ratuszny; Catarina Hadamitzky; Haijiao Zhang; Rainer Blasczyk; Constança Figueiredo
Journal:  Mol Med       Date:  2015-04-09       Impact factor: 6.354

2.  Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer.

Authors:  Hua Shen; Jianxin Shen; Lin Wang; Zhumei Shi; Min Wang; Bing-Hua Jiang; Yongqian Shu
Journal:  Biomed Pharmacother       Date:  2014-12-19       Impact factor: 6.529

3.  An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration.

Authors:  Raghu R Chivukula; Guanglu Shi; Asha Acharya; Eric W Mills; Lauren R Zeitels; Joselin L Anandam; Abier A Abdelnaby; Glen C Balch; John C Mansour; Adam C Yopp; Anirban Maitra; Joshua T Mendell
Journal:  Cell       Date:  2014-05-22       Impact factor: 41.582

4.  TGFβ Triggers miR-143/145 Transfer From Smooth Muscle Cells to Endothelial Cells, Thereby Modulating Vessel Stabilization.

Authors:  Montserrat Climent; Manuela Quintavalle; Michele Miragoli; Ju Chen; Gianluigi Condorelli; Leonardo Elia
Journal:  Circ Res       Date:  2015-03-23       Impact factor: 17.367

5.  Tumor-suppressive microRNAs in Lung cancer: diagnostic and therapeutic opportunities.

Authors:  Lorenzo F Sempere; Xi Liu; Ethan Dmitrovsky
Journal:  ScientificWorldJournal       Date:  2009-07-13

Review 6.  MicroRNAs in Cancer.

Authors:  Ramiro Garzon; George A Calin; Carlo M Croce
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

7.  Decreased expression of microRNA-143 and -145 in human gastric cancers.

Authors:  Takeshi Takagi; Akio Iio; Yoshihito Nakagawa; Tomoki Naoe; Nobuhiko Tanigawa; Yukihiro Akao
Journal:  Oncology       Date:  2009-05-12       Impact factor: 2.935

8.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase.

Authors:  Michel DuPage; Alison L Dooley; Tyler Jacks
Journal:  Nat Protoc       Date:  2009-06-25       Impact factor: 13.491

9.  Small RNA combination therapy for lung cancer.

Authors:  Wen Xue; James E Dahlman; Tuomas Tammela; Omar F Khan; Sabina Sood; Apeksha Dave; Wenxin Cai; Leilani M Chirino; Gillian R Yang; Roderick Bronson; Denise G Crowley; Gaurav Sahay; Avi Schroeder; Robert Langer; Daniel G Anderson; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

10.  Negative feedback regulation of calcineurin-dependent Prz1 transcription factor by the CaMKK-CaMK1 axis in fission yeast.

Authors:  Eugenia Cisneros-Barroso; Tula Yance-Chávez; Ayako Kito; Reiko Sugiura; Alba Gómez-Hierro; David Giménez-Zaragoza; Rosa Aligue
Journal:  Nucleic Acids Res       Date:  2014-07-31       Impact factor: 16.971

View more
  63 in total

1.  The MicroRNA miR-210 Is Expressed by Cancer Cells but Also by the Tumor Microenvironment in Triple-Negative Breast Cancer.

Authors:  Isabelle Bar; Ahmad Merhi; Fadi Abdel-Sater; Abduelhakem Ben Addi; Sara Sollennita; Jean-Luc Canon; Paul Delrée
Journal:  J Histochem Cytochem       Date:  2017-04-12       Impact factor: 2.479

2.  In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL.

Authors:  Eleanor R C Fiedler; Arjun Bhutkar; Emily Lawler; Rana Besada; Michael T Hemann
Journal:  Blood Adv       Date:  2018-06-12

3.  Rev7 dimerization is important for assembly and function of the Rev1/Polζ translesion synthesis complex.

Authors:  Alessandro A Rizzo; Faye-Marie Vassel; Nimrat Chatterjee; Sanjay D'Souza; Yunfeng Li; Bing Hao; Michael T Hemann; Graham C Walker; Dmitry M Korzhnev
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-15       Impact factor: 11.205

4.  Circular RNA circDLGAP4 is involved in lung cancer development through modulating microRNA-143/CDK1 axis.

Authors:  Bin Wang; Peiyan Hua; Bin Zhao; Jindong Li; Yan Zhang
Journal:  Cell Cycle       Date:  2020-07-09       Impact factor: 4.534

Review 5.  MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis.

Authors:  Keiko Mizuno; Hiroko Mataki; Naohiko Seki; Tomohiro Kumamoto; Kazuto Kamikawaji; Hiromasa Inoue
Journal:  J Hum Genet       Date:  2016-08-04       Impact factor: 3.172

6.  The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance.

Authors:  Annalisa Del Prete; Francesca Sozio; Tiziana Schioppa; Andrea Ponzetta; William Vermi; Stefano Calza; Mattia Bugatti; Valentina Salvi; Giovanni Bernardini; Federica Benvenuti; Annunciata Vecchi; Barbara Bottazzi; Alberto Mantovani; Silvano Sozzani
Journal:  Cancer Immunol Res       Date:  2019-09-04       Impact factor: 11.151

7.  miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1.

Authors:  Ming Zhan; Xiaonan Zhao; Hui Wang; Wei Chen; Sunwang Xu; Wei Wang; Hui Shen; Shuai Huang; Jian Wang
Journal:  Tumour Biol       Date:  2016-02-08

8.  Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival.

Authors:  Vasilena Gocheva; Alexandra Naba; Arjun Bhutkar; Talia Guardia; Kathryn M Miller; Carman Man-Chung Li; Talya L Dayton; Francisco J Sanchez-Rivera; Caroline Kim-Kiselak; Noor Jailkhani; Monte M Winslow; Amanda Del Rosario; Richard O Hynes; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-26       Impact factor: 11.205

9.  Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids.

Authors:  Sarah E LeBoeuf; Warren L Wu; Triantafyllia R Karakousi; Burcu Karadal; S RaElle Jackson; Shawn M Davidson; Kwok-Kin Wong; Sergei B Koralov; Volkan I Sayin; Thales Papagiannakopoulos
Journal:  Cell Metab       Date:  2019-12-05       Impact factor: 27.287

10.  BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency.

Authors:  Manav Gupta; Carla P Concepcion; Caroline G Fahey; Hasmik Keshishian; Arjun Bhutkar; Christine F Brainson; Francisco J Sanchez-Rivera; Patrizia Pessina; Jonathan Y Kim; Antoine Simoneau; Margherita Paschini; Mary C Beytagh; Caroline R Stanclift; Monica Schenone; D R Mani; Chendi Li; Audris Oh; Fei Li; Hai Hu; Angeliki Karatza; Roderick T Bronson; Alice T Shaw; Aaron N Hata; Kwok-Kin Wong; Lee Zou; Steven A Carr; Tyler Jacks; Carla F Kim
Journal:  Cancer Res       Date:  2020-07-20       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.